Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
May 31, 2011
Results of Special Meeting
May 31, 2011
Neuren CEO Presentation to AGM
May 20, 2011
Neuren reduces outstanding convertible note principal
May 19, 2011
Neuren's Perseis selects lead antibodies
May 13, 2011
Notice of Special Shareholders Meeting/Proxy Form
May 11, 2011
Neuren Completes Phase II trial Cohort 1
May 06, 2011
Notice under section 708A(5)(e) of the Corporations Act
May 06, 2011
Appendix 3B
May 05, 2011
Becoming a substantial holder
May 04, 2011
Neuren Announces Private Placement and Rights Issue
Previous
1
2
3
4
5
6
7
8
9
Next
